Table 1:
Case Information
| Case Number | Sex | Age | PMI, hour | Braak Stage | Aβ plaque A39/40 | Diagnoses | Figures Using Case |
|---|---|---|---|---|---|---|---|
| Alzheimer’s Disease | |||||||
| 11–09 | M | 77 | 5.5 | VI | Moderate | AD/ Atherosclerosis/CAA | Figure 1d, 2a, 2b |
| 11–17 | F | 69 | 3.6 | VI | Frequent | AD/CAA | Figure 2d |
| 12–12 | F | 82 | 7 | VI | Frequent | AD | Figure 5 (AD8) |
| 12–13 | F | 95 | 6.2 | VI | Frequent | AD/CAA/Vascular Dementia | Figure 4 |
| 13–14 | F | 63 | 6.5 | VI | Frequent | AD/Hippocampal Sclerosis/CAA | Figure 4 |
| 16–12 | F | ≥90 | 5.16 | VI | Moderate | AD/CAA | Figure 2a, 2b |
| 16–15 | F | 55 | 5.57 | VI | Frequent | AD/Arteriolar Sclerosis/CAA/Hippocampal Sclerosis | Figure 3d |
| 17–18 | M | 81 | 6.58 | VI | Moderate | AD/ Atherosclerosis/CAA/ Vascular Dementia | Figure 4 |
| 2–12 | F | 64 | 5.3 | V | Frequent | AD/CAA | Figure 2a, 2b |
| 21–11 | M | 96 | 5.4 | VI | Frequent | AD/Atherosclerotic Leukoencephalopathy/ Arterial Sclerosis/ CAA/Hippocampal Sclerosis |
Figure 4 |
| 21–12 | M | 90 | 3.5 | V | Moderate | AD/Atherosclerosis/Hippocampal Sclerosis | Figure 4 |
| 21–17 | M | ≥90 | 5.32 | V | Moderate | AD/Atherosclerosis/Hemorrhages | Figure 2d |
| 22–16 | M | 90 | 5.42 | VI | Moderate | AD/Atherosclerosis/ Hemorrhage |
Figure 4 |
| 22–17 | M | 90 | 6.08 | V | Sparse | AD/Atherosclerosis/CAA/Lewy Bodies (Amygdala) | Figure 4 |
| 22–18 | F | 89 | 5.25 | VI | Moderate | AD | Figure 4 |
| 23–11 | M | 71 | 6.2 | IV | Frequent | AD | Figure 5 (AD7) |
| 24–12 | F | ≥90 | 7.41 | V | Sparse | AD/Arterial Sclerosis/Atherosclerosis/Hippocampal Sclerosis/Solitary Infarct | Figure 2a, 2b |
| 24–17 | F | ≥90 | 4.43 | VI | Frequent | AD/CAA | Figure 2d |
| 25–10 | F | 57 | 3.55 | VI | Frequent | AD | Figure 1d, 2d, 3c (AD5) |
| 28–11 | M | 81 | 4 | VI | Moderate | AD/CAA/Multiple Infarctions/Trauma | Figure 1d, 2d |
| 29–15 | M | 83 | 4.73 | V | Moderate | AD/CAA | Figure 2d, 2e |
| 3–12 | M | 81 | 5 | IV | Sparse | AD/Atherosclerosis | Figure 2b |
| 3–13 | F | ≥90 | 4.66 | VI | Frequent | AD/Diffuse LB/Hippocampal Sclerosis | Figure 1d, 2a, 2b, 2d, 3a, 3c (AD1 for Figure 3) |
| 3–16 | F | 72 | 5.42 | IV | Frequent | AD | Figure 2d |
| 30–10 | M | 46 | 5.3 | VI | Moderate | AD/CAA/Vascular Dementia | Figure 1d, 2d |
| 31–11 | F | ≥90 | 3.55 | V | Frequent | AD/Hippocampal Sclerosis | Figure 2a, 2b, 2d |
| 33–09 | M | 93 | 6.36 | VI | Frequent | AD/Arteriolar Sclerosis/Atherosclerosis/CAA | Figure 4 |
| 33–14 | F | 73 | 5.75 | VI | Frequent | AD | Figure 2a, 2b |
| 34–12 | F | ≥90 | 5 | VI | Sparse | AD/CAA/Hippocampal Sclerosis | Figure 2d |
| 34–13 | M | 46 | 4.6 | VI | Frequent | AD/CAA/Vascular Dementia | Figure 2a, 2b |
| 37–10 | F | 88 | 5.3 | V | Frequent | AD/Subcortical Arteriosclerotic Leukoencephalopathy | Figure 2d, 4 |
| 37–12 | M | ≥90 | 5.41 | VI | Moderate | AD/ Arteriosclerosis /Atherosclerosis/Micro-hemorrhages | Figure 1a–1c, 1d, 2d, 2e |
| 37–15 | F | 87 | 6.03 | VI | Frequent | AD/Atherosclerosis/Meningioma | Figure 4 |
| 38–11 | M | ≥90 | 5.5 | V | Moderate | AD | Figure 1d, 2a, 2b, 2d |
| 42–16 | F | 74 | 4.53 | V | Frequent | AD/CAA/Diffuse LB | Figure 4 |
| 47–16 | F | ≥90 | 6.92 | VI | Moderate | AD | Figure 1d, 2d |
| 48–17 | F | 92 | 5.03 | VI | Moderate | AD/Atherosclerosis | Figure 3c, 3e, 4 |
| 5–13 | F | ≥90 | 4.92 | V | Frequent | AD/Atherosclerosis/CAA/ Vascular Dementia |
Figure 1g, 2a, 2b, 2d, 3a, 3c (AD2 for Fig. 3) |
| 6–14 | F | 64 | 6.15 | VI | Moderate | AD | Figure 2d |
| 8–13 | M | ≥90 | 4.85 | V | Sparse | AD/Atherosclerosis/Hippo campal Sclerosis |
Figure 2d, 2e |
| 805 | F | ≥90 | 8.5 | V | Frequent | AD/Arteriosclerosis/Atherosclerosis/CAA | Figure 1d |
| 811 | M | 59 | 5.5+ | VI | Frequent | AD/CAA/hydrocephalus | Figure 2a, 2b, 2d |
| 813 | M | 79 | 5.75 | V | Frequent | AD/CAA | Figure 2a, 2b |
| 869 | F | 75 | 5 | VI | Moderate | AD | Figure 2a, 2b |
| 871 | F | 88 | 9 | V | Sparse | AD/CAA/Cerebral Contusion/Hippocampal Sclerosis | Figure 2a, 2b |
| 9–18 | F | 89 | 4.87 | V | Frequent | AD/Ischemic leukoencephalopathy/ Atherosclerosis/Vascular Dementia |
Figure 4 |
| 900 | M | 87 | 5.5 | V-VI | Frequent | AD/CAA | Figure 1d, 1e–1f, 2d |
| 909 | M | 86 | 5.5+ | V | Frequent | AD/CAA/Ependymitis | Figure 2d |
| U1 | F | 96 | 5 | VI | Frequent | AD/CAA/Cerebrovascular Disease | Figure 2d |
| U2 | M | 82 | 5 | V-VI | Moderate | AD/CAA/Cerebrovascular Disease | Figure 1d, 2a, 2b |
| 7–11 | F | ≥90 | 4.25 | III | Moderate | CIND/Atherosclerosis | Figure 5 (AD6) |
| Tauopathy | |||||||
| 19–12 | M | ≥90 | 5.91 | III | None | Hippocampal Sclerosis | Figure 5 (T3) |
| 20–12 | F | ≥90 | 7.5 | IV | Sparse | Hippocampal Sclerosis | Figure 5 (T4) |
| 23–12 | F | ≥90 | 6 | III | None | CAA/Solitary Infarct/Hippocampal Sclerosis | Figure 5 (T2) |
| 31–12 | M | ≥90 | 6 | IV | None | Hippocampal Sclerosis | Figure 5 (T5) |
| U3 | M | 75 | 8 | IV | None | NFT-predominant AD/Arteriosclerosis/ Atherosclerosis |
Figure 5 (T1) |
| Controls | |||||||
| 1–13 | M | ≥90 | 6 | I | None | Atherosclerosis/Solitary Infarct | Figure 5 (N1) |
| 830 | F | 89 | 4.25 | II | None | AD/vascular dementia/atrophy | Figure 3a (Con) |
| 907 | M | 84 | 5 | N/A | None | Normal | Figure 5 (N2) |
Plaques number in the area (based on Bielschowsky stain and IHC): None = 0; Sparse = 1–5; Moderate = 6–20; Frequent = more than 20. CIND: Cognitive impairment, no dementia; CAA: Cerebral amyloid angiopathy.